| External factors: | 5-Aza-20-Deoxycytidine |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Cancer |
| Experiment: | SA-β-gal activity assay//SAHF//Immunostaining//Cytokine array |
| Description: | Incubation with 5-aza-dC led to a significant increase (P < 0.001) in the number of SA-β-gal–positive HepG2 cells；We therefore investigated SAHF formation by immunofluorescence microscopy of H3K9me3 in HepG2 cells.Treatment with 20mmol/L 5-aza-dC for 72 hours triggered not only the typical increase of cell size, but also resulted in the characteristic accumulation of H3K9me3 in subnuclear dots.The incubation with 5-azadC caused increased levels of sICAM-1, interleukin (IL)1ra, and IL-8 in the culture supernatants. |
| Target gene: | P16//P53 |
| R-EF-Target gene: | Upregulation//Upregulation |
| Official symbol(s): | P16//P53 |
| Target gene experiment: | Immunohistochemistry//Western blot |
| Target gene description: | In this experimental setting, only 5-aza-dC but not 5-aza-CR induced an upre-gulation of p16(INK4a)；In contrast, 5-aza-dC rather led to an increase in p53 protein levels, which might be related to the senescence-inducing capacity of this drug. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: